Tech Company Financing Transactions
Biolex Funding Round
Polaris Partners, Intersouth Partners and Johnson & Johnson Development Corporation joined a $36 million Series B funding round for Biolex. The round was announced on 9/1/2005.
Transaction Overview
Company Name
Announced On
9/1/2005
Transaction Type
Venture Equity
Amount
$36,000,000
Round
Series B
Investors
Polaris Partners (Lead Investor) (Kevin Bitterman)
Proceeds Purpose
Biolex plans to use proceeds from the financing to fund clinical development of its lead product candidates, and to continue to expand and enhance its Good Manufacturing Practice biomanufacturing capabilities to support its internal drug development and partner protein programs.
Company Information
Company Status
Out of Business
Industry
Biopharmaceutical
Mailing Address
158 Credle St.
Pittsboro, NC 27312
USA
Pittsboro, NC 27312
USA
Phone
Website
Email Address
Overview
Biolex, Inc. is a biopharmaceutical company devoted to discovering, developing and commercializing its proprietary advanced protein expression technology for the development of human therapeutics.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Jan Turek
Chief Financial Officer
Dale Sander
Chief Medical Officer
Walker Long
VP - Bus. Development
Bipin Dalmia
VP - R & D
Lynn Dickey
VP - R & D
David Spencer
Browse more venture capital transactions:
Prev: 9/1/2005: Akimbi Systems venture capital transaction
Next: 9/2/2005: Quellan venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on every notable VC transaction. VC transactions on this site are sourced from a variety of public sources. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs